European Child & Adolescent Psychiatry

, 18:418

Olanzapine compared to quetiapine in adolescents with a first psychotic episode

Authors

    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • Olalla Robles
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • Mara Parellada
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • David Fraguas
    • Department of PsychiatryHospital Infanta Sofia
  • Ana Ruiz-Sancho
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • Oscar Medina
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • Arantzazu Zabala
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
  • Igor Bombín
    • Neurological Rehabilitation Center
  • Dolores Moreno
    • Psychiatry Department, Adolescent UnitHospital General Universitario Gregorio Marañón, Centro de Investigación Biomédica en Red de Salud Mental, CIBERSAM
ORIGINAL CONTRIBUTION

DOI: 10.1007/s00787-009-0749-5

Cite this article as:
Arango, C., Robles, O., Parellada, M. et al. Eur Child Adolesc Psychiatry (2009) 18: 418. doi:10.1007/s00787-009-0749-5

Abstract

Objective

To compare the efficacy, safety, and tolerability of olanzapine and quetiapine in adolescents with first episode psychosis.

Method

Fifty adolescents (age 16 ± 1.25) with a first episode of psychosis were randomized to quetiapine or olanzapine in a 6-month open label study. Efficacy and side effect scales, as well as vital signs and laboratory data were recorded at baseline, 7, 15, 30, 90, and 180 days (end of study).

Results

Out of the total sample included in the study, 32 patients completed the trial (quetiapine n = 16, olanzapine n = 16). Patients in both treatment groups had a significant reduction in all clinical scales with the exception of the negative scale of the Positive and Negative Symptom Scale (PANSS) for olanzapine and the general psychopathology scale of the PANSS for quetiapine. The only difference between treatment arms on the clinical scales was observed on the patients’ strength and difficulties questionnaire (SDQ) scale, with greater improvement for olanzapine. Patients on olanzapine gained 15.5 kg and patients on quetiapine gained 5.5 kg.

Conclusion

Olanzapine and quetiapine reduced psychotic symptoms in this adolescent sample. Patients on olanzapine gained significantly more weight. Side effects with both drugs seemed to be more prevalent than those reported in adult studies.

Keywords

olanzapine quetiapine safety tolerability adolescent first episode psychosis

Copyright information

© Steinkopff Verlag Darmstadt 2009